Newsroom

Nanyang Biologics is excited to share that its latest research, LigoSpace, developed in collaboration with Nanyang Technological University Singapore (NTU), has been presented at NeurIPS 2025, one of the world’s most prestigious conferences in AI and ML.

Privacy and Security Policy of Nanyang Biologics.

Nanyang Biologics is pleased to announce that we will be exhibiting at NVIDIA GTC 2026, taking place from March 16–19, 2026.

Nanyang Biologics has been featured as a global case study by @Equinix, showcasing how our AI-driven drug discovery is powered by scalable and secure infrastructure.

Nanyang Biologics has been crowned the 1st Prize Winner of the SuperAI Genesis Startup Competition 2025, the world’s premier AI startup showdown at SuperAI Singapore 2025.

We’re incredibly excited to share that Nanyang Biologics has been featured in the NVIDIA’s official video spotlighting standout startups at NVIDIA GTC Taipei 2025.

Nanyang Biologics (NYB) made a strong presence at COMPUTEX 2025, one of the world's premier technology exhibitions, held from May 20–23 at the Taipei Nangang Exhibition Center. The event, themed "AI Next," brought together global leaders in artificial intelligence, robotics, and next-generation technologies who are driving the future of innovation.

Nanyang Biologics will be joining GITEX ASIA – Asia’s largest and most global tech, startup, and digital investment event – taking place from April 23 to 25 at Marina Bay Sands, Singapore.

A pioneering collaboration with Nanyang Technological University Singapore with the NYB - NTU Joint Laboratory, aiming at revolutionizing drug discovery through the power of AI and natural compounds.

Nanyang Biologics' AI-driven DTIGN platform revolutionizes natural compound drug discovery with great accuracy, efficiency, and speed, unlocking nature's vast therapeutic potential for breakthrough treatments.

Nanyang Biologics announced the signing of a business combination agreement with RF Acquisition Corp II, aiming to bring NYB to the public markets.

Nanyang Biologics hosts AI4Life Summit 2025 with global partners – NVIDIA, Hewlett Packard Enterprise, and Equinix – to accelerate AI-Driven biomedical innovation

NYB.AI and Pnaseer Inc. have entered a strategic partnership to accelerate hair follicle regeneration research by combining AI-powered compound prediction with advanced bio-nanoparticle drug delivery.

Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have partnered to combine AI-powered compound discovery with advanced genetic risk profiling - bringing a new dimension to precision health through nature-derived interventions.

Nanyang Biologics is revolutionizing drug discovery with AI at NVIDIA GTC 2025! Discover how we’re using the latest technologies to accelerate life-saving innovations.

Nanyang Biologics becomes a resident company of JLABS, joining a global network dedicated to accelerating life-enhancing health and wellness solutions.

Nanyang Biologics harnesses NVIDIA AI and accelerated computing to transform $7 billion drug discovery industry.

Nanyang Biologics' Vecura platform, powered by NVIDIA GPU infrastructure, is rewriting the rules of natural ingredient discovery.

Advancing Bioactivity Prediction Through Molecular Docking and Self-Attention.